SPI-1005
Hearing loss in Meniere's Disease
Key Facts
About Sound Pharmaceuticals
Sound Pharmaceuticals is a clinical-stage biotech pioneering first-in-class therapeutics for inner ear disorders, a significant unmet medical need affecting tens of millions in the US alone. Its lead asset, SPI-1005, has received FDA Breakthrough Therapy Designation for hearing loss in Meniere's disease, highlighting its potential. The company leverages a seasoned leadership team with deep expertise in otology and drug development to advance a pipeline focused on otoprotection, chemoprotection, and hair cell regeneration.
View full company profileAbout Sound Pharmaceuticals
Sound Pharmaceuticals is a clinical-stage biotech pioneering first-in-class therapeutics for inner ear disorders, a significant unmet medical need affecting tens of millions in the US alone. Its lead asset, SPI-1005, has received FDA Breakthrough Therapy Designation for hearing loss in Meniere's disease, highlighting its potential. The company leverages a seasoned leadership team with deep expertise in otology and drug development to advance a pipeline focused on otoprotection, chemoprotection, and hair cell regeneration.
View full company profileAbout Sound Pharmaceuticals
Sound Pharmaceuticals is a clinical-stage biotech pioneering first-in-class therapeutics for inner ear disorders, a significant unmet medical need affecting tens of millions in the US alone. Its lead asset, SPI-1005, has received FDA Breakthrough Therapy Designation for hearing loss in Meniere's disease, highlighting its potential. The company leverages a seasoned leadership team with deep expertise in otology and drug development to advance a pipeline focused on otoprotection, chemoprotection, and hair cell regeneration.
View full company profile